FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017178741> ?p ?o ?g. }

• W2017178741 endingPage "602" @default.
• W2017178741 startingPage "596" @default.
• W2017178741 abstract "Environmental exposure to lead (Pb) early in life results in a latent upregulation of genes and products associated with Alzheimer's disease (AD), particularly the plaque forming protein amyloid beta (Aβ). Furthermore, animals exposed to Pb as infants develop cognitive decline and memory impairments in old age. Studies from our lab demonstrated that tolfenamic acid lowers the levels of the amyloid β precursor protein (APP) and its aggregative cleavage product Aβ by inducing the degradation of the transcription factor specificity protein 1 (Sp1). These changes were accompanied by cognitive improvement in transgenic APP knock-in mice. In this study, we examined the effects of tolfenamic acid on beta site APP cleaving enzyme 1 (BACE1) which is responsible for Aβ production and tested its ability to reverse Pb-induced upregulation in the amyloidogenic pathway. Mice were administered tolfenamic acid for one month and BACE1 gene expression as well as its enzymatic activity were analyzed in the cerebral cortex. Tolfenamic acid was also tested for its ability to reverse changes in Sp1, APP and Aβ that were upregulated by Pb in vitro. Differentiated SH-SY5Y neuroblastoma cells were either left unexposed, or sequentially exposed to Pb followed by tolfenamic acid. Our results show that tolfenamic acid reduced BACE1 gene expression and enzyme activity in mice. In neuroblastoma cells, Pb upregulated Sp1, APP and Aβ, while tolfenamic acid lowered their expression. These results along with previous data from our lab provide evidence that tolfenamic acid, a drug that has been used for decades for migraine, represents a candidate which can reduce the pathology of AD and may mitigate the damage of environmental risk factors associated with this disease." @default.
• W2017178741 created "2016-06-24" @default.
• W2017178741 creator A5045836130 @default.
• W2017178741 creator A5071917754 @default.
• W2017178741 creator A5090318779 @default.
• W2017178741 date "2014-04-01" @default.
• W2017178741 modified "2023-09-25" @default.
• W2017178741 title "Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers" @default.
• W2017178741 cites W1411024041 @default.
• W2017178741 cites W1493502680 @default.
• W2017178741 cites W1565463013 @default.
• W2017178741 cites W1693568153 @default.
• W2017178741 cites W1964474096 @default.
• W2017178741 cites W1967237003 @default.
• W2017178741 cites W1969389830 @default.
• W2017178741 cites W1991435932 @default.
• W2017178741 cites W1994544330 @default.
• W2017178741 cites W1997322102 @default.
• W2017178741 cites W1999973557 @default.
• W2017178741 cites W2000706612 @default.
• W2017178741 cites W2003283600 @default.
• W2017178741 cites W2011885084 @default.
• W2017178741 cites W2014556730 @default.
• W2017178741 cites W2022231372 @default.
• W2017178741 cites W2032602280 @default.
• W2017178741 cites W2033067082 @default.
• W2017178741 cites W2033382511 @default.
• W2017178741 cites W2035120902 @default.
• W2017178741 cites W2035613313 @default.
• W2017178741 cites W2038838498 @default.
• W2017178741 cites W2041231034 @default.
• W2017178741 cites W2045394310 @default.
• W2017178741 cites W2046972756 @default.
• W2017178741 cites W2067915140 @default.
• W2017178741 cites W2078515060 @default.
• W2017178741 cites W2080274663 @default.
• W2017178741 cites W2081030499 @default.
• W2017178741 cites W2085693623 @default.
• W2017178741 cites W2093426751 @default.
• W2017178741 cites W2094590592 @default.
• W2017178741 cites W2096410114 @default.
• W2017178741 cites W2096749156 @default.
• W2017178741 cites W2099236418 @default.
• W2017178741 cites W2103440561 @default.
• W2017178741 cites W2112533118 @default.
• W2017178741 cites W2118539817 @default.
• W2017178741 cites W2124726981 @default.
• W2017178741 cites W2129489564 @default.
• W2017178741 cites W2132259157 @default.
• W2017178741 cites W2159677246 @default.
• W2017178741 cites W2163304386 @default.
• W2017178741 cites W2164829288 @default.
• W2017178741 cites W2165165188 @default.
• W2017178741 cites W2318447699 @default.
• W2017178741 cites W2969438869 @default.
• W2017178741 doi "https://doi.org/10.1016/j.neuropharm.2014.01.009" @default.
• W2017178741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7057722" @default.
• W2017178741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24462621" @default.
• W2017178741 hasPublicationYear "2014" @default.
• W2017178741 type Work @default.
• W2017178741 sameAs 2017178741 @default.
• W2017178741 citedByCount "35" @default.
• W2017178741 countsByYear W20171787412014 @default.
• W2017178741 countsByYear W20171787412015 @default.
• W2017178741 countsByYear W20171787412016 @default.
• W2017178741 countsByYear W20171787412017 @default.
• W2017178741 countsByYear W20171787412018 @default.
• W2017178741 countsByYear W20171787412019 @default.
• W2017178741 countsByYear W20171787412020 @default.
• W2017178741 countsByYear W20171787412021 @default.
• W2017178741 countsByYear W20171787412022 @default.
• W2017178741 countsByYear W20171787412023 @default.
• W2017178741 crossrefType "journal-article" @default.
• W2017178741 hasAuthorship W2017178741A5045836130 @default.
• W2017178741 hasAuthorship W2017178741A5071917754 @default.
• W2017178741 hasAuthorship W2017178741A5090318779 @default.
• W2017178741 hasBestOaLocation W20171787412 @default.
• W2017178741 hasConcept C104317684 @default.
• W2017178741 hasConcept C126322002 @default.
• W2017178741 hasConcept C127561419 @default.
• W2017178741 hasConcept C153911025 @default.
• W2017178741 hasConcept C185592680 @default.
• W2017178741 hasConcept C2776156579 @default.
• W2017178741 hasConcept C2779134260 @default.
• W2017178741 hasConcept C2779281246 @default.
• W2017178741 hasConcept C31705614 @default.
• W2017178741 hasConcept C36103677 @default.
• W2017178741 hasConcept C41007966 @default.
• W2017178741 hasConcept C502032728 @default.
• W2017178741 hasConcept C55493867 @default.
• W2017178741 hasConcept C71924100 @default.
• W2017178741 hasConcept C86803240 @default.
• W2017178741 hasConcept C98274493 @default.
• W2017178741 hasConceptScore W2017178741C104317684 @default.
• W2017178741 hasConceptScore W2017178741C126322002 @default.
• W2017178741 hasConceptScore W2017178741C127561419 @default.
• W2017178741 hasConceptScore W2017178741C153911025 @default.
• W2017178741 hasConceptScore W2017178741C185592680 @default.

• next